Literature DB >> 32555424

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections.

Quan-Xin Long1, Xiao-Jun Tang2, Qiu-Lin Shi2, Qin Li3, Hai-Jun Deng1, Jun Yuan1, Jie-Li Hu1, Wei Xu2, Yong Zhang2, Fa-Jin Lv4, Kun Su3, Fan Zhang5, Jiang Gong5, Bo Wu6, Xia-Mao Liu7, Jin-Jing Li7, Jing-Fu Qiu8, Juan Chen9, Ai-Long Huang10.   

Abstract

The clinical features and immune responses of asymptomatic individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have not been well described. We studied 37 asymptomatic individuals in the Wanzhou District who were diagnosed with RT-PCR-confirmed SARS-CoV-2 infections but without any relevant clinical symptoms in the preceding 14 d and during hospitalization. Asymptomatic individuals were admitted to the government-designated Wanzhou People's Hospital for centralized isolation in accordance with policy1. The median duration of viral shedding in the asymptomatic group was 19 d (interquartile range (IQR), 15-26 d). The asymptomatic group had a significantly longer duration of viral shedding than the symptomatic group (log-rank P = 0.028). The virus-specific IgG levels in the asymptomatic group (median S/CO, 3.4; IQR, 1.6-10.7) were significantly lower (P = 0.005) relative to the symptomatic group (median S/CO, 20.5; IQR, 5.8-38.2) in the acute phase. Of asymptomatic individuals, 93.3% (28/30) and 81.1% (30/37) had reduction in IgG and neutralizing antibody levels, respectively, during the early convalescent phase, as compared to 96.8% (30/31) and 62.2% (23/37) of symptomatic patients. Forty percent of asymptomatic individuals became seronegative and 12.9% of the symptomatic group became negative for IgG in the early convalescent phase. In addition, asymptomatic individuals exhibited lower levels of 18 pro- and anti-inflammatory cytokines. These data suggest that asymptomatic individuals had a weaker immune response to SARS-CoV-2 infection. The reduction in IgG and neutralizing antibody levels in the early convalescent phase might have implications for immunity strategy and serological surveys.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32555424     DOI: 10.1038/s41591-020-0965-6

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  1010 in total

1.  Rapid single-molecule detection of COVID-19 and MERS antigens via nanobody-functionalized organic electrochemical transistors.

Authors:  Keying Guo; Shofarul Wustoni; Anil Koklu; Escarlet Díaz-Galicia; Maximilian Moser; Adel Hama; Ahmed A Alqahtani; Adeel Nazir Ahmad; Fatimah Saeed Alhamlan; Muhammad Shuaib; Arnab Pain; Iain McCulloch; Stefan T Arold; Raik Grünberg; Sahika Inal
Journal:  Nat Biomed Eng       Date:  2021-05-24       Impact factor: 25.671

Review 2.  Practical guidance for clinical laboratories for SARS-CoV-2 serology testing.

Authors:  Carmen Charlton; Jamil Kanji; Vanessa Tran; Julianne Kus; Jonathan Gubbay; Carla Osiowy; Jason Robinson; Inna Sekirov; Michael Drebot; Todd Hatchette; Derek Stein; Nadia El-Gabalawy; Amanda Lang; Lei Jiao; Paul Levett; Heidi Wood; Christian Therrien; L Robbin Lindsay; Muhammad Morshed; Jessica Forbes; Antonia Dibernardo
Journal:  Can Commun Dis Rep       Date:  2021-05-07

Review 3. 

Authors:  Paul Van Caeseele; Dana Bailey; Sarah E Forgie; Tanis C Dingle; Mel Krajden
Journal:  CMAJ       Date:  2020-12-07       Impact factor: 8.262

4.  SARS-CoV-2 reinfection.

Authors:  I Romera; K Núñez; M Calizaya; I Baeza; R Molina; J Morillas
Journal:  Med Intensiva (Engl Ed)       Date:  2021-02-10

5.  Had COVID? You'll probably make antibodies for a lifetime.

Authors:  Ewen Callaway
Journal:  Nature       Date:  2021-05-26       Impact factor: 49.962

6.  A Pragmatic Approach to Immunity & Respiratory Viral Infections.

Authors:  Todd A Born
Journal:  Integr Med (Encinitas)       Date:  2020-10

7.  RIG-I triggers a signaling-abortive anti-SARS-CoV-2 defense in human lung cells.

Authors:  Taisho Yamada; Seiichi Sato; Yuki Sotoyama; Yasuko Orba; Hirofumi Sawa; Hajime Yamauchi; Michihito Sasaki; Akinori Takaoka
Journal:  Nat Immunol       Date:  2021-05-11       Impact factor: 25.606

8.  Effectiveness of infection-containment measures on SARS-CoV-2 seroprevalence and circulation from May to July 2020, in Milan, Italy.

Authors:  Valeria Cento; Claudia Alteri; Marco Merli; Federica Di Ruscio; Livia Tartaglione; Roberto Rossotti; Giovanna Travi; Marta Vecchi; Alessandro Raimondi; Alice Nava; Luna Colagrossi; Roberto Fumagalli; Nicola Ughi; Oscar Massimiliano Epis; Diana Fanti; Andrea Beretta; Filippo Galbiati; Francesco Scaglione; Chiara Vismara; Massimo Puoti; Daniela Campisi; Carlo Federico Perno
Journal:  PLoS One       Date:  2020-11-20       Impact factor: 3.240

Review 9.  Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement.

Authors:  Daniel Lenihan; Joseph Carver; Charles Porter; Jennifer E Liu; Susan Dent; Paaladinesh Thavendiranathan; Joshua D Mitchell; Anju Nohria; Michael G Fradley; Iskra Pusic; Keith Stockerl-Goldstein; Anne Blaes; Alexander R Lyon; Sarju Ganatra; Teresa López-Fernández; Rupal O'Quinn; Giorgio Minotti; Sebastian Szmit; Daniela Cardinale; Jose Alvarez-Cardona; Giuseppe Curigliano; Tomas G Neilan; Joerg Herrmann
Journal:  CA Cancer J Clin       Date:  2020-09-10       Impact factor: 508.702

Review 10.  Age-related susceptibility to coronavirus infections: role of impaired and dysregulated host immunity.

Authors:  Rudragouda Channappanavar; Stanley Perlman
Journal:  J Clin Invest       Date:  2020-12-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.